Pien Tze Huang's Controlling Shareholder Completes Share Purchase Plan, Accumulating Approximately 500 Million Yuan

Jiulong River Group Completes Share Purchase Plan

In the latest news from May, Pien Tze Huang (600436) announced that its controlling shareholder, Zhangzhou Jiulong River Group Co., Ltd. (hereinafter referred to as "Jiulong River Group") has completed its share purchase plan. From February 1 to April 30, 2026, Jiulong River Group accumulated 3.1713 million shares through centralized competitive trading, accounting for 0.53% of the company's total share capital, with a cumulative purchase amount of approximately 500 million yuan, meeting the lower limit of the previously announced purchase plan.

Purchase Details and Shareholding Changes

According to the announcement, upon completion of this share purchase plan, Jiulong River Group holds a total of approximately 311 million shares in Pien Tze Huang, representing a 51.50% stake. As Pien Tze Huang's controlling shareholder, Jiulong River Group has further consolidated its controlling position through this purchase, while also signaling confidence in the company's long-term development to the market.

In terms of purchasing pace, Jiulong River Group completed all operations within the three-month purchase window, acquiring 3.1713 million shares at a total cost of approximately 500 million yuan. Based on these figures, the average purchase price was approximately 157.7 yuan per share, indicating the controlling shareholder's endorsement of the company's current valuation.

Market Signal Interpretation

A substantial share purchase by a controlling shareholder is generally regarded as a positive signal by the market. On one hand, it demonstrates the major shareholder's optimistic outlook on the company's fundamentals and future growth prospects. On the other hand, the tangible financial commitment helps stabilize market expectations and bolster investor confidence.

As a leading traditional Chinese medicine (TCM) enterprise in China, Pien Tze Huang has been steadily advancing its digital transformation and smart manufacturing upgrades in recent years. Amid the broader trend of deep integration between the pharmaceutical industry and artificial intelligence, Pien Tze Huang is actively exploring the application of AI technologies in drug research and development, quality control, and supply chain management to enhance its core competitiveness.

Outlook

With the successful completion of the controlling shareholder's share purchase plan, Pien Tze Huang's ownership structure has become more stable. Against the backdrop of the pharmaceutical industry's accelerating embrace of digital and intelligent transformation, Pien Tze Huang — backed by strong shareholder support — is well-positioned to maintain its leading edge at the intersection of traditional Chinese medicine and modern technology. The market will continue to monitor the company's further developments in business expansion and technological innovation.